Dochek® Multi-Drug Urine Test Dipcard Rx; Dochek® Multi-Drug Urine Test Dipcard

K240698 · Guangzhou Decheng Biotechnology Co., Ltd. · DJG · May 10, 2024 · Clinical Toxicology

Device Facts

• Record ID: K240698
• Device Name: Dochek® Multi-Drug Urine Test Dipcard Rx; Dochek® Multi-Drug Urine Test Dipcard
• Applicant: Guangzhou Decheng Biotechnology Co., Ltd.
• Product Code: DJG · Clinical Toxicology
• Decision Date: May 10, 2024
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3650
• Device Class: Class 2

Intended Use

Dochek® Multi-Drug Urine Test Dipcard Rx is an immunoassay for the qualitative determination of single or multiple drugs in human urine at the following cutoff concentrations: [Table of drugs/cutoffs]. Dochek® Multi-Drug Urine Test Dipcard Rx offers any combinations from 1 to 16 drugs but only one cutoff concentration under same drug condition will be included per device. It is intended for prescription use. For in vitro diagnostic use only. The test provides only preliminary results. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. GC/MS or LC/MS is the recommended confirmatory method. Dochek® Multi-Drug Urine Test Dipcard is an immunoassay for the qualitative determination of single or multiple drugs in human urine at the following cutoff concentrations: [Table of drugs/cutoffs]. Dochek® Multi-Drug Urine Test Dipcard offers any combinations from 1 to 16 drugs but only one cutoff concentration under same drug condition will be included per device. It is intended for over-the-counter (OTC) use. For in vitro diagnostic use only. The test provides only preliminary results. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. GC/MS or LC/MS is the recommended confirmatory method.

Device Story

Lateral flow immunochromatographic assay for qualitative drug screening in human urine. Device consists of test strips integrated into plastic dipcard; absorbent end contacts urine sample. Principle: competitive immunoassay; drug in sample competes with drug-protein conjugate for limited monoclonal antibody binding sites. Negative result: colored line in Test Region (T) indicates drug below detection level. Positive result: absence of line in Test Region (T) indicates drug at or above detection level. Control line (C) confirms proper test performance. Used in clinical or home settings; operated by healthcare professionals or lay users. Provides preliminary results; requires professional judgment and confirmatory testing (GC/MS or LC/MS) for clinical decision-making.

Clinical Evidence

Bench testing only. Precision/reproducibility studies performed across 25 days using three lots. Analytical specificity/cross-reactivity evaluated against numerous compounds. Method comparison study performed with 80 clinical samples per drug compared to LC/MS. Lay user study conducted with 280 participants across three sites using various drug concentrations confirmed by LC/MS, demonstrating high accuracy.

Technological Characteristics

Lateral flow immunochromatographic assay. Materials: plastic dipcard with integrated test strips. Principle: competitive binding. Energy source: none (capillary action). Connectivity: none. Sterilization: not stated. Software: none.

Indications for Use

Indicated for qualitative detection of single or multiple drugs of abuse in human urine. Intended for prescription (Rx) or over-the-counter (OTC) use. Provides preliminary results; requires confirmatory testing (GC/MS or LC/MS).

Regulatory Classification

Identification

An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• Dochek® Multi-Drug Urine Test Cup Rx, Dochek® Multi-Drug Urine Test Cup (K232659)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. Underneath the square are the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Guangzhou Decheng Biotechnology Co., Ltd. Mango Huang Regulatory Affairs Manager Floor 3/4/5/7, Building A1, No.12, Nanyun 1st Road Science City, Huangpu District Guangzhou, 510663 China

Re: K240698

Trade/Device Name: Dochek® Multi-Drug Urine Test Dipcard Rx; Dochek® Multi-Drug Urine Test Dipcard Regulation Number: 21 CFR 862.3650 Regulation Name: Opiate Test System Regulatory Class: Class II Product Code: DJG, NFT, DKZ, PTH, DIS, NGL, NFV, JXM, NFY, DIO, PTG, DJR, NGG, DJC, NGM, LCM, QBF, JXN, QAW, LFG, NFW, LDJ Dated: March 14, 2024 Received: March 14, 2024

Dear Mango Huang:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Joseph A. Digitally signed by Joseph A. Kotarek - Kotarek - S Date: 2024.05.09 S 14:56:49 -04'00'

Joseph Kotarek Branch Chief

{2}------------------------------------------------

Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

# Indications for Use

510(k) Number (if known) K240698

## Device Name

Dochek® Multi-Drug Urine Test Dipcard Rx

## Indications for Use (Describe)

Dochek® Multi-Drug Urine Test Dipcard Rx is an immunoassay for the qualitative determination of single or multiple drugs in human urine at the following cutoff concentrations:

| Drug (Identifier) |
|----------------------------------------------------------|
| Amphetamine (AMP) |
| Secobarbital (BAR) |
| Buprenorphine (BUP) |
| Oxazepam (BZO) |
| Cocaine (COC) |
| 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) |
| Methylenedioxymethamphetamine (MDMA) |
| Methamphetamine (MET) |
| Morphine (MOP/OPI) |
| Methadone (MTD) |
| Oxycodone (OXY) |
| Phencyclidine (PCP) |
| Propoxyphene (PPX) |
| Nortriptyline (TCA) |
| Cannabinoids (THC) |
| 6-Monoacetylmorphine (6-MAM) |

Cut-off level 1000 or 500 ng/mL 300 ng/mL 10 ng/mL 300 ng/mL 300 or 150 ng/mL 300 ng/mL 500 ng/mL 1000 or 500 ng/mL 300 or 2000 ng/mL 300 ng/mL 100 ng/mL 25 ng/mL 300 ng/mL 1000 ng/mL 50 ng/mL 10 ng/mL

Dochek® Multi-Drug Urine Test Dipcard Rx offers any combinations from 1 to 16 drugs but only one cutoff concentration under same drug condition will be included per device. It is intended for prescription use. For in vitro diagnostic use only.

The test provides only preliminary results. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. GC/MS is the recommended confirmatory method.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

## CONTINUE ON A SEPARATE PAGE IF NEEDED.

{4}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

## *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{5}------------------------------------------------

# Indications for Use

510(k) Number (if known) K240698

## Device Name

Dochek® Multi-Drug Urine Test Dipcard

## Indications for Use (Describe)

Dochek® Multi-Drug Urine Test Dipcard is an immunoassay for the qualitative determination of single or multiple drugs in human urine at the following cutoff concentrations:

> Cut-off level 1000 or 500 ng/mL

300 ng/mL 10 ng/mL 300 ng/mL

300 ng/mL 100 ng/mL 25 ng/mL 300 ng/mL 1000 ng/mL 50 ng/mL 10 ng/mL

300 or 150 ng/mL 300 ng/mL 500 ng/mL

1000 or 500 ng/mL 300 or 2000 ng/mL

| Drug (Identifier) |
|----------------------------------------------------------|
| Amphetamine (AMP) |
| Secobarbital (BAR) |
| Buprenorphine (BUP) |
| Oxazepam (BZO) |
| Cocaine (COC) |
| 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) |
| Methylenedioxymethamphetamine (MDMA) |
| Methamphetamine (MET) |
| Morphine (MOP/OPI) |
| Methadone (MTD) |
| Oxycodone (OXY) |
| Phencyclidine (PCP) |
| Propoxyphene (PPX) |
| Nortriptyline (TCA) |
| Cannabinoids (THC) |
| 6-Monoacetylmorphine (6-MAM) |

Dochek® Multi-Drug Urine Test Dipcard offers any combinations from 1 to 16 drugs but only one cutoff concentration under same drug condition will be included per device. It is intended for over-the-counter (OTC) use. For in vitro diagnostic use only.

The test provides only preliminary results. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. GC/MS or LC/MS is the recommended confirmatory method.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

X Over-The-Counter Use (21 CFR 801 Subpart C)

## CONTINUE ON A SEPARATE PAGE IF NEEDED.

{6}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

## *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{7}------------------------------------------------

# 510(k) SUMMARY

# 510(k) number: k240698

- Date: May 9, 2024 1. Submitter: Submitter: Guangzhou Decheng Biotechnology Co., Ltd. 2. Address: Floor 3/4/5/7, Building A1, No.12, Nanyun 1st Road, Science City, Huangpu District, Guangzhou, Guangdong, 510663, P.R. China Contact Person: Mango Huang Contact Email Address: mango.huang(@)dochekbio.com Telephone: [phone] Correspondent: Correspondent: Guangzhou Decheng Biotechnology Co., Ltd. 3. Address: Floor 3/4/5/7, Building A1, No.12, Nanyun 1st Road, Science City, Huangpu District, Guangzhou, Guangdong, 510663, P.R. China Contact Person: Mango Huang Contact Email Address: mango.huang(@dochekbio.com Telephone: [phone]. Device Name: Dochek® Multi-Drug Urine Test Dipcard Rx Dochek® Multi-Drug Urine Test Dipcard
#### 5. Classification: Class II

| Product Code | Regulation Section | Panel |
|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------|------------|
| Target Drug | | |
| DKZ, NFT<br>Amphetamine (AMP) | 862.3100, Amphetamine Test System | Toxicology |
| DIS, PTH<br>Secobarbital (BAR) | 862.3150, Barbiturate Test System | Toxicology |
| DJG, NGL<br>Buprenorphine (BUP)<br>Morphine (MOP/OPI)<br>Oxycodone (OXY)<br>6-Monoacetylmorphine (6-MAM) | 862.3650, Opiate Test System | Toxicology |
| JXM, NFV<br>Oxazepam (BZO) | 862.3170, Benzodiazepine Test System | Toxicology |
| DIO, NFY<br>Cocaine (COC) | 862.3250, Cocaine and cocaine<br>metabolite test system | Toxicology |
| DJR, PTG<br>2-ethylidene-1,5-dimethyl-3,3-<br>diphenylpyrrolidine (EDDP)<br>Methadone (MTD) | 862.3620, Methadone Test System | Toxicology |

{8}------------------------------------------------

| DJC, NGG<br>Methylenedioxymethamphetamine<br>(MDMA)<br>Methamphetamine (MET) | 862.3610,<br>Methamphetamine Test System | Toxicology |
|------------------------------------------------------------------------------|--------------------------------------------------------|------------|
| LCM, NGM<br>Phencyclidine (PCP) | Unclassified | Toxicology |
| JXN, QBF<br>Propoxyphene (PPX) | 862.3700 Propoxyphene test system. | Toxicology |
| LFG, QAW<br>Nortriptyline (TCA) | 862.3910 Tricyclic antidepressant<br>drugs test system | Toxicology |
| LDJ, NFW<br>Cannabinoids (THC) | 862.3870, Cannabinoids Test System | Toxicology |

### Predicate Devices 6.

| K232659 | Dochek® Multi-Drug Urine Test Cup Rx |
|---------|--------------------------------------|
| K232659 | Dochek® Multi-Drug Urine Test Cup |

# 7. Intended Use

Dochek® Multi-Drug Urine Test Dipcard Rx is an immunoassay for the qualitative determination of single or multiple drugs in human urine at the following cutoff concentrations:

| Drug (Identifier) | Cut-off level |
|----------------------------------------------------------|-------------------|
| Amphetamine (AMP) | 1000 or 500 ng/mL |
| Secobarbital (BAR) | 300 ng/mL |
| Buprenorphine (BUP) | 10 ng/mL |
| Oxazepam (BZO) | 300 ng/mL |
| Cocaine (COC) | 300 or 150 ng/mL |
| 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) | 300 ng/mL |
| Methylenedioxymethamphetamine (MDMA) | 500 ng/mL |
| Methamphetamine (MET) | 1000 or 500 ng/mL |
| Morphine (MOP/OPI) | 300 or 2000 ng/mL |
| Methadone (MTD) | 300 ng/mL |
| Oxycodone (OXY) | 100 ng/mL |
| Phencyclidine (PCP) | 25 ng/mL |
| Propoxyphene (PPX) | 300 ng/mL |
| Nortriptyline (TCA) | 1000 ng/mL |
| Cannabinoids (THC) | 50 ng/mL |
| 6-Monoacetylmorphine (6-MAM) | 10 ng/mL |

Dochek® Multi-Drug Urine Test Dipcard Rx offers any combinations from 1 to 16 drugs but only one cutoff concentration under same drug condition will be included per device. It is intended for prescription use. For in vitro diagnostic use only.

{9}------------------------------------------------

The test provides only preliminary results. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. GC/MS or LC/MS is the recommended confirmatory method.

Dochek® Multi-Drug Urine Test Dipcard is an immunoassay for the qualitative determination of single or multiple drugs in human urine at the following cutoff concentrations:

| Drug (Identifier) | Cut-off level |
|----------------------------------------------------------|-------------------|
| Amphetamine (AMP) | 1000 or 500 ng/mL |
| Secobarbital (BAR) | 300 ng/mL |
| Buprenorphine (BUP) | 10 ng/mL |
| Oxazepam (BZO) | 300 ng/mL |
| Cocaine (COC) | 300 or 150 ng/mL |
| 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) | 300 ng/mL |
| Methylenedioxymethamphetamine (MDMA) | 500 ng/mL |
| Methamphetamine (MET) | 1000 or 500 ng/mL |
| Morphine (MOP/OPI) | 300 or 2000 ng/mL |
| Methadone (MTD) | 300 ng/mL |
| Oxycodone (OXY) | 100 ng/mL |
| Phencyclidine (PCP) | 25 ng/mL |
| Propoxyphene (PPX) | 300 ng/mL |
| Nortriptyline (TCA) | 1000 ng/mL |
| Cannabinoids (THC) | 50 ng/mL |
| 6-Monoacetylmorphine (6-MAM) | 10 ng/mL |

Dochek® Multi-Drug Urine Test Dipcard offers any combinations from 1 to 16 drugs but only one cutoff concentration under same drug condition will be included per device.

# It is intended for over-the-counter (OTC) use. For in vitro diagnostic use only.

The test provides only preliminary results. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. GC/MS or LC/MS is the recommended confirmatory method.

### Device Description 8.

Dochek® Multi-Drug Urine Test Dipcard Rx and Dochek® Multi-Drug Urine Test Dipcard are immunochromatographic assays that use a lateral flow system for the qualitative detection of single or multiple drugs in human urine at or above the cut-off levels as indicated. The products are singleuse in vitro diagnostic devices.

This device is a dipcard format in which the test strips are integrated into the plastic dipcard. After removing the cap of the dipcard, the absorbent end of the test strips is exposed and can be in direct

{10}------------------------------------------------

contact with the urine sample. The device is in a ready-to-use format and no longer requires assembly before use.

| Similarities | | |
|------------------------------------|---------------------------------------------------------------------------------------------------------|-------------------------------|
| Item | New Device | Predicate Device<br>(K232659) |
| Intended use | Qualitative detection of drugs of abuse in urine.<br>For prescription use or over-the-counter use | Same |
| Methodology | Competitive binding, lateral flow<br>immunochromatographic assay based on antigen-<br>antibody reaction | Same |
| Type of Test | Qualitative | Same |
| Specimen Type | Human urine | Same |
| Target Drug<br>and Cutoff<br>Value | Target Drug | Cutoff<br>(ng/mL) |
| | Amphetamine (AMP) | 1000 or 500 |
| | Secobarbital (BAR) | 300 |
| | Buprenorphine (BUP) | 10 |
| | Oxazepam (BZO) | 300 |
| | Cocaine (COC) | 300 or 150 |
| | 2-ethylidene-1,5-dimethyl-3,3-<br>diphenylpyrrolidine (EDDP) | 300 |
| | Methylenedioxymethamphetamine<br>(MDMA) | 500 |
| | Methamphetamine (MET) | 1000 or 500 |
| | Morphine (MOP300/OPI2000) | 2000 or 300 |
| | Methadone (MTD) | 300 |
| | Oxycodone (OXY) | 100 |
| | Phencyclidine (PCP) | 25 |
| | Propoxyphene (PPX) | 300 |
| | Nortriptyline (TCA) | 1000 |
| | Cannabinoids (THC) | 50 |
| | 6-Monoacetylmorphine (6-MAM) | 10 |
| Differences | | |
| Configurations | Test dipcard | Test cup |

### Substantial Equivalence Information 9.

# 10. Standard/Guidance Document Reference (if applicable)

None referenced.

# 11. Test Principle

Dochek® Multi-Drug Urine Test Dipcard Rx or Dochek® Multi-Drug Urine Test Dipcard is a

{11}------------------------------------------------

competitive immunoassay that is used to screen for the presence of various drugs and drug metabolites in urine. It is chromatographic absorbent device in which, drugs within a urine sample, competitively combined to a limited number of drug monoclonal antibody (mouse) conjugate binding sites.

When the test is activated, the urine is absorbed into each test strip by capillary action, mixes with the respective drug monoclonal antibody conjugate, and flows across a pre-coated membrane. When drug in the urine sample is below the detection level of the test, respective drug monoclonal antibody conjugate binds to the respective drug-protein conjugate immobilized in the Test Region (T) of the test strip. This produces a colored Test line in the Test Region (T) of the strip, which, regardless of its intensity, indicates a negative test result.

When drug level is at or above the detection level of the tree drug in the sample binds to the respective drug monoclonal antibody conjugate, preventing the respective drug monoclonal antibody conjugate from binding to the respective drug-protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band in the test region, indicating a preliminary positive result.

To serve as a procedure control, a colored line will appear at the Control Region (C) of each strip, if the test has been performed properly.

# 12. Performance Characteristics

# A. Analytical Performance

# a. Precision/Reproducibility:

Precision studies were carried out for samples with concentrations of +100% cutoff, +50% cutoff, +25% cutoff, cutoff, -25% cutoff, -50% cutoff, -75% cut off and -100% cutoff. Other samples were prepared by spiked target drug in drug-free urine samples. Each drug concentration was confirmed by LC-MS/MS. For each concentration, tests were performed two runs per day for 25 days using three lots of test dipcard. The results obtained are summarized in the following tables:

| Drug | Lot<br>Number | +100%<br>cutoff | +75%<br>cutoff | +50%<br>cutoff | +25%<br>cutoff | Cutoff | -25%<br>cutoff | -50%<br>cutoff | -75%<br>cutoff | -100%<br>cut-off |
|-------------|---------------|-----------------|----------------|----------------|----------------|---------|----------------|----------------|----------------|------------------|
| AMP<br>1000 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 13-/37+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| 1000 | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 13-/37+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| BAR<br>300 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| 300 | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| BUP<br>10 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 16-/34+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| 10 | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| BZO<br>300 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 11-/39+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| 300 | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 13-/37+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| COC | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 13-/37+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| 300 | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| EDDP | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 13-/37+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| 300 | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| MDM A 500 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 10-/40+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 10-/40+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 11-/39+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| MET 1000 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 11-/39+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 10-/40+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 11-/39+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| OPI 2000 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 10-/40+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 9-/41+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 10-/40+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| MTD 300 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| OXY 100 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 13-/37+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| PCP 25 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 16-/34+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| PPX 300 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| TCA 1000 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 11-/39+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 11-/39+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| THC 50 | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 13-/37+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| 6-MAM | Lot I | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot II | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot III | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| AMP 500 | Lot IV | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot V | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot VI | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| COC 150 | Lot IV | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot V | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot VI | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| MET | Lot IV | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| 500 | Lot V | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 13-/37+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot VI | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 12-/38+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| MOP | Lot IV | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| 300 | Lot V | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 15-/35+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |
| | Lot VI | 0-/50+ | 0-/50+ | 0-/50+ | 0-/50+ | 14-/36+ | 50-/0+ | 50-/0+ | 50-/0+ | 50-/0+ |

{12}------------------------------------------------

{13}------------------------------------------------

# b. Linearity/assay reportable range:

Not applicable. This device is intended for qualitative use only.

# c. Stability:

The device can be stable at 2-30°C for 36 months based on real time stability study.

# d. Detection limit:

Not applicable.

# e. Analytical specificity/Interference:

# Cross-Reactivity:

Analytical specificity for this device was determined through adding the potential interfering substances to drug-free urine samples. The relative cross-reactivity represents the minimum concentration necessary to yield a result similar to the cutoff level of the respective assay. Percent cross-reactivity, provided in the below table, was calculated as the concentration of analyte tested that yielded a positive result, divided by the cutoff concentration, multiplied by 100. If no cross reactivity was observed, the highest concentration tested is shown.

| Drug/Cutoff | Compound | Concentration<br>(ng/mL) | % Cross-Reactivity |
|---------------------------------|---------------------------------------------------------|--------------------------|--------------------|
| AMP 1000 | d-Amphetamine | 1,000 | 100% |
| | d/l-Amphetamine | 3,000 | 33.3% |
| | l-Amphetamine | 50,000 | 2% |
| | (+/-) 3,4-<br>methylenedioxyamphetamine<br>(MDA) | 5,000 | 20% |
| | Phentermine | 3,000 | 33.3% |
| | Hydroxyamphetamine | 10,000 | 10% |
| | d-Methamphetamine | 100,000(Negative) | Not detected |
| | l-Methamphetamine | 100,000(Negative) | Not detected |
| | (+/-)3,4-<br>Methylenedioxyethylamphetamine<br>(MDEA) | 100,000(Negative) | Not detected |
| | (+/-)3,4-<br>Methylenedioxymethamphetamine<br>(MDMA) | 100,000(Negative) | Not detected |
| | (1R,2S)-(-)-Ephedrine | 100,000(Negative) | Not detected |
| | β-Phenylethylamine | 100,000 | 1% |
| | Tyramine | 100,000 | 1% |
| | p-Hydroxynorephedrine | 100,000 | 1% |
| | Phenylpropanolamine | 100,000(Negative) | Not detected |
| | (±)Phenylpropanolamine | 100,000(Negative) | Not detected |
| | p-Hydroxyamphetamine | 100,000 | 1% |
| | d/l-Norephedrine | 100,000 | 1% |
| | Benzphetamine | 100,000(Negative) | Not detected |
| | 1-Epinephrine | 100,000(Negative) | Not detected |
| | d/l-Epinephrine | 100,000(Negative) | Not detected |
| | Secobarbital | 300 | 100% |
| | Amobarbital | 1,000 | 30% |
| | Alphenal | 75 | 400% |
| | Aprobarbital | 250 | 120% |
| BAR 300 | Butabarbital | 100 | 300% |
| | Butalbital | 5,000 | 6% |
| | Butethal | 500 | 60% |
| | Cyclopentobarbital | 500 | 60% |
| | Pentobarbital | 200 | 150% |
| | Phenobarbital | 300 | 100% |
| | Buprenorphine | 10 | 100% |
| | Norbuprenorphine | 50 | 20% |
| | Buprenorphine 3-D-glucuronide | 10 | 100% |
| BUP 10 | Norbuprenorphine 3-D-<br>glucuronide | 10 | 100% |
| | Morphine | 100000 (Negative) | Not Detected |
| | Oxymorphone | 100000 (Negative) | Not Detected |
| | Hydromorphone | 100000 (Negative) | Not Detected |
| | Oxazepam | 300 | 100% |
| | Alprazolam | 150 | 200% |
| | α-Hydroxyalprazolam | 1,500 | 20% |
| | Bromazepam | 100 | 300% |
| | Chlordiazepoxide | 500 | 60% |
| | Clobazam | 750 | 40% |
| | Clonazepam | 1,500 | 20% |
| | Clorazepate dipotassium | 100 | 300% |
| | Diazepam | 500 | 60% |
| | Estazolam | 500 | 60% |
| | Flunitrazepam | 2,500 | 12% |
| BZO 300 | Midazolam | 2,000 | 15% |
| | Nitrazepam | 2,000 | 15% |
| | Nordiazepam | 500 | 60% |
| | Temazepam | 250 | 120% |
| | Triazolam | 1,000 | 30% |
| | Desalkylflurazepam | 500 | 60% |
| | Lorazepam | 5,000 | 6% |
| | Norchlordiazepoxide | 500 | 60% |
| | Nordazepam | 1,000 | 30% |
| | Delorazepam | 2,000 | 15% |
| | Demoxepam | 5,000 | 6% |
| | Flurazepam | 500 | 60% |
| | Benzoylecgonine | 300 | 100% |
| | Cocaine HCl | 750 | 40% |
| | Cocaethylene | 12,500 | 2.4% |
| COC 300 | Ecgonine | 30,000 | 1% |
| | Ecgonine methyl ester | 100,000(negative) | Not detected |
| | Norcocaine | 100,000(negative) | Not detected |
| | 2-ethylidene-1,5-dimethyl-3,3- | 300 | 100% |
| | diphenylpyrrolidine | | |
| EDDP 300 | Methadone | 100,000(negative) | Not detected |
| | EMDP | 100,000(negative) | Not detected |
| | Doxylamine | 100,000(negative) | Not detected |
| | Levacetylmethadol (LAAM) | 100,000(negative) | Not detected |
| | Disopyramide | 100,000(negative) | Not detected |
| | Alpha Methadol | 100,000(negative) | Not detected |
| MDMA 500 | (+/-)3,4-<br>Methylenedioxymethamphetamine<br>HCI(MDMA) | 500 | 100% |
| | (+/-)3,4-<br>Methylenedioxyamphetamine HCl<br>(MDA) | 3,000 | 17% |
| | (+/-)3,4-<br>Methylenedioxyethylamphetamine<br>(MDEA) | 300 | 167% |
| | d-Methamphetamine | 100,000(Negative) | Not detected |
| | d-Amphetamine | 100,000(Negative) | Not detected |
| | 1-Methamphetamine | 100,000(Negative) | Not detected |
| | 1-Amphetamine | 100,000(Negative) | Not detected |
| | d-Methamphetamine | 1,000 | 100% |
| | d-Amphetamine | 50,000 | 2% |
| | Chloroquine | 50,000 | 2% |
| | (1R,2S)-(-)-Ephedrine | 50,000 | 2% |
| | (-)-Methamphetamine | 25,000 | 4% |
| MET 1000 | (+/-)3,4-<br>methylenedioxumethamphetamine<br>(MDMA) | 4,000 | 25% |
| | β-Phenylethylamine | 50,000 | 2% |
| | Trimethobenzamide | 10,000 | 10% |
| | 1-Amphetamine | 75,000 | 1.3% |
| | (+/-)3,4-<br>Methylenedioxyethylamphetamine<br>(MDEA) | 30,000 | 3.3% |
| | Mephentermine | 50,000 | 2% |
| | Methoxyphenamine | 50,000 | 2% |
| | Fenfluramine | 75,000 | 1.3% |
| | Procaine | 100,000(Negative) | Not detected |
| | d/l-Amphetamine | 100,000(Negative) | Not detected |
| | p-Hydroxymethamphetamine | 30,000 | 3.3% |
| | l-Phenylephrine | 100,000(Negative) | Not detected |
| | d/l-Methamphetamine | 1,000 | 100% |
| | (+/-) 3,4-<br>Methylenedioxyamphetamine<br>(MDA) | 100,000(Negative) | Not detected |
| | Morphine | 2,000 | 100% |
| | Codeine | 2,000 | 100% |
| | Hydrocodone | 12,500 | 16% |
| | Hydromorphone | 5,000 | 40% |
| | 6-Monoacetylmorphine | 1,500 | 133% |
| | Morphine 3-β-D-glucuronide | 2,000 | 100% |
| | Ethylmorphine | 1,500 | 133% |
| | Diacetylmorphine (heroin) | 2,000 | 100% |
| OPI 2000 | Levorphanol | 75,000 | 2.7% |
| | Norcodeine | 12,500 | 16% |
| | Oxycodone | 100,000(Negative) | Not detected |
| | Thebaine | 5,000 | 40% |
| | Normorphine | 50,000 | 4% |
| | Oxymorphone | 100,000(Negative) | Not detected |
| | Procaine | 100,000(Negative) | Not detected |
| | Codeine-6-β-D-glucuronide | 3,000 | 67% |
| | d-Norpropoxyphene hydrochloride | 5,000 | 40% |
| | Methadone | 300 | 100% |
| MTD 300 | EDDP | 100,000(Negative) | Not detected |
| | Doxylamine | 50,000 | 0.6% |
| | Levacetylmethadol (LAAM) | 100,000(negative) | Not detected |
| | EMDP | 100,000(negative) | Not detected |
| | Alpha Methadol | 100,000(negative) | Not detected |
| | Oxycodone | 100 | 100% |
| OXY 100 | Hydrocodone | 5,000 | 2% |
| | Hydromorphone | 50,000 | 0.2% |
| | Oxymorphone | 1,000 | 10% |
| | Codeine | >100,000 | Not detected |
| | Ethylmorphine | >100,000 | Not detected |
| | Dihydrocodeine | 20,000 | 0.5% |
| | Oxymorphone-3β-D- glucuronide | 5,000 | 2% |
| | Morphine | 100,000(negative) | Not detected |
| | 6-Monoacetylmorphine | 100,000(negative) | Not detected |
| | Buprenorphine | 100,000(negative) | Not detected |
| | Thebaine | 100,000(negative) | Not detected |
| | Phencyclidine | 25 | 100% |
| PCP 25 | 4-Hydroxy Phencyclidine | 1,500 | 1.7% |
| | d-Propoxyphene | 300 | 100% |
| PPX 300 | d-Norpropoxyphene | 300 | 100% |
| | Nortriptyline | 1,000 | 100% |
| | Nordoxepin | 1,000 | 100% |
| | Trimipramine | 3,000 | 33.3% |
| | Promazine | 1,500 | 66.7% |
| | Desipramine | 200 | 500% |
| | Imipramine | 750 | 133% |
| TCA 1000 | Clomipramine | 10,000 | 10% |
| | Doxepin | 1,250 | 80% |
| | Maprotiline | 2,000 | 50% |
| | Amitriptyline | 1,500 | 66.7% |
| | Promethazine | 25,000 | 4% |
| | Cyclobenzaprine | 1,000 | 100% |
| | Norclomipramine | 12,500 | 8% |
| | 11-nor-Δ9-THC-9-COOH | 50 | 100% |
| THC 50 | 11-nor-Δ8-THC-9-COOH | 30 | 167% |
| | (±)-11-Hydroxy-Δ9-THC | 2,500 | 2% |
| | Δ8- Tetrahydrocannabinol | 2,000 | 2.5% |
| | Δ9- Tetrahydrocannabinol | 5,000 | 1% |
| | Cannabinol | 10,000 | 0.5% |
| | Cannabidiol(CBD) | 100,000 | 0.05% |
| | (±)-11-nor-9-carboxy-Δ9-THC | 100 | 50% |
| | 11-nor-Δ9-THC-carboxy<br>glucuronide | | |
| 6-MAM | 6-Monoacetylmorphine | 10 | 100% |
| | Codeine | 100,000(Negative) | Not detected |
| | Ethylmorphine | 100,000(Negative) | Not detected |
| | Hydrocodone | 50,000 | 0.02% |
| | Hydromorphone | 10,000 | 0.1% |
| | Levorphanol | 100,000(Negative) | Not detected |
| | Morphine 3-β-D-glucuronide | 100,000(Negative) | Not detected |
| | Morphine | 100,000 | 0.01% |
| | Norcodeine | 100,000(Negative) | Not detected |
| | Normorphine | 100,000(Negative) | Not detected |
| | Oxycodone | 100,000(Negative) | Not detected |
| | Oxymorphone | 10,000 | 0.1% |
| | Procaine | 50,000 | 0.02% |
| | Thebaine | 10,000 | 0.1% |
| | Diacetylmorphine (heroin) | 25 | 40% |
| 10 | Acetylcodeine | 10,000(Negative) | <0.1% |
| | Buprenorphine | 10,000(Negative) | <0.1% |
| | Dihydrocodeine | 10,000(Negative) | <0.1% |
| | Nalorphine | 5,000 | 0.2% |
| | Dextromethorphan | 100,000(Negative) | Not detected |
| | Imipramine | 100,000(Negative) | Not detected |
| | Levacetylmethadol (LAAM) | 100,000(Negative) | Not detected |
| | Meperidine | 100,000(Negative) | Not detected |
| | Methadone | 100,000(Negative) | Not detected |
| | Mitragynine (kratom) | 20,000(Negative) | <0.05% |
| | Morphine 6-D-glucuronide | 100,000(Negative) | Not detected |
| | Naloxone | 100,000(Negative) | Not detected |
| | Naltrexone | 100,000(Negative) | Not detected |
| | Naproxen | 100,000(Negative) | Not detected |
| | Norbuprenorphine | 10,000(Negative) | <0.1% |
| | Norbuprenorphine glucuronide | 100,000(Negative) | Not detected |
| | Norhydrocodone | 100,000(Negative) | Not detected |
| | | | |
| | Noroxycodone | 100,000(Negative) | Not detected |
| | Noroxymorphone | 100,000(Negative) | Not detected |
| | Norpropoxyphene | 100,000(Negative) | Not detected |
| | Oxymorphone-3β-D- glucuronide | 100,000(Negative) | Not detected |
| | Tapentadol HCl | 100,000(Negative) | Not detected |
| | Tramadol | 100,000(Negative) | Not detected |
| | d-Amphetamine | 500 | 100% |
| | d/l-Amphetamine | 1,500 | 33.3% |
| | l-Amphetamine | 25,000 | 2% |
| | (+/-) 3,4-<br>methylenedioxyamphetamine<br>(MDA) | 2,500 | 20% |
| | Phentermine | 1,500 | 33.3% |
| | Hydroxyamphetamine | 5,000 | 10% |
| | d-Methamphetamine | 100,000(Negative) | Not detected |
| | l-Methamphetamine | 100,000(Negative) | Not detected |
| AMP 500 | (+/-)3,4-<br>Methylenedioxyethylamphetamine<br>(MDEA) | 100,000(Negative) | Not detected |
| | (+/-)3,4-<br>Methylenedioxymethamphetamine<br>(MDMA) | 100,000(Negative) | Not detected |
| | (1R,2S)-(-)-Ephedrine | 100,000(Negative) | Not detected |
| | β-Phenylethylamine | 100,000 | 0.5% |
| | Tyramine | 100,000 | 0.5% |
| | p-Hydroxynorephedrine | 100,000 | 0.5% |
| | Phenylpropanolamine | 100,000(Negative) | Not detected |
| | (±)Phenylpropanolamine | 100,000(Negative) | Not detected |
| | p-Hydroxyamphetamine | 100,000 | 0.5% |
| | d/l-Norephedrine | 100,000 | 0.5% |
| | Benzphetamine | 100,000(Negative) | Not detected |
| | l-Epinephrine | 100,000(Negative) | Not detected |
| | d/l-Epinephrine | 100,000(Negative) | Not detected |
| COC 150 | Benzoylecgonine | 150 | 100% |
| | | | |
| | Cocaine HCl | 500 | 30% |
| | Cocaethylene | 5,000 | 3% |
| | Ecgonine | 15,000 | 1% |
| | Ecgonine methyl ester | 100,000(negative) | Not detected |
| | Norcocaine | 100,000(negative) | Not detected |
| | d-Methamphetamine | 500 | 100% |
| | d-Amphetamine | 25,000 | 2% |
| | Chloroquine | 25,000 | 2% |
| | (1R,2S)-(-)-Ephedrine | 25,000 | 2% |
| | (-)-Methamphetamine | 12,500 | 4% |
| | (+/-)3,4-<br>methylenedioxumethamphetamine<br>(MDMA) | 2,000 | 25% |
| | β-Phenylethylamine | 25,000 | 2% |
| | Trimethobenzamide | 5,000 | 10% |
| | l-Amphetamine | 50,000 | 1% |
| MET 500 | (+/-)3,4-<br>Methylenedioxyethylamphetamine<br>(MDEA) | 15,000 | 3.3% |
| | Mephentermine | 25,000 | 2% |
| | Methoxyphenamine | 25,000 | 2% |
| | Fenfluramine | 37,500 | 1.3% |
| | Procaine | >100,000 | Not detected |
| | d/l-Amphetamine | 75,000 | 0.7% |
| | p-Hydroxymethamphetamine | 15,000 | 3.3% |
| | l-Phenylephrine | >100,000 | Not detected |
| | d/l-Methamphetamine | 500 | 100% |
| | (+/-) 3,4-<br>Methylenedioxyamphetamine<br>(MDA) | 75,000 | 0.7% |
| MOP 300 | Morphine | 300 | 100% |
| | Codeine | 300 | 100% |
| | Hydrocodone | 5,000 | 6% |
| | Hydromorphone | 1,000 | 30% |
| 6-Monoacetylmorphine | 150 | 200% | |
| Morphine 3-β-D-glucuronide | 1,000 | 30% | |
| Ethylmorphine | 100 | 300% | |
| Diacetylmorphine (heroin) | 300 | 100% | |
| Levorphanol | 10,000 | 3% | |
| Norcodeine | 5,000 | 6% | |
| Oxycodone | 75,000 | 0.4% | |
| Thebaine | 3,000 | 10% | |
| Normorphine | 3,000 | 10% | |
| Oxymorphone | 25,000 | 1.2% | |
| Procaine | 100,000(Negative) | Not detected | |
| Codeine-6-β-D-glucuronide | 500 | 60% | |
| d-Norpropoxyphene hydrochloride | 300 | 100% | |

{14}------------------------------------------------

{15}------------------------------------------------

{16}------------------------------------------------

{17}------------------------------------------------

{18}------------------------------------------------

{19}------------------------------------------------

{20}------------------------------------------------

{21}------------------------------------------------

{22}------------------------------------------------

# Interfering Substances:

To evaluate potential interference, non-structurally related compounds were added to drug-free urine and to urine samples containing the target drugs at 25% below and 25% above each corresponding cutoff. Compounds that show no interference at a concentration of 100μg/mL are summarized in the following table.

| 3-Hydroxytyramine | Diflunisal | Oxalic Acid |
|--------------------------------|----------------------------|---------------------------------------------|
| Acetaminophen | Digoxin | Oxolinic Acid |
| Acetylsalicylic Acid | Diphenhydramine | Oxymetazoline |
| Acyclovir | Dopamine HCl | Paliperidone |
| Albumin (100 mg/dL)…